Sharps Technology (STSS) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
24 Dec, 2025Meeting overview
Special meeting of stockholders called to order on March 28, 2025, at 10:00 A.M. Eastern Time.
Board members and key executives, including the CEO, CFO, and company founder, were introduced.
Inspector of election appointed and formalities for quorum and voting confirmed.
Quorum and voting details
January 29, 2025, set as the record date for voting eligibility.
11,077,997 shares outstanding; 4,334,176 votes represented, equating to 39.12% voting power.
Quorum established, exceeding the 33% threshold required to transact business.
Proposals presented
Proposal to authorize a reverse stock split at a ratio between 1-for-3 and 1-for-11 to regain NASDAQ compliance.
Proposal to authorize issuance of warrants and underlying shares related to a recent securities offering.
Proposal to approve adjournment of the meeting if more time is needed to solicit votes for the above proposals.
Latest events from Sharps Technology
- First revenues, $50M U.S. deal, and expansion into high-margin prefilled syringes drive growth.STSS
Life Sciences Virtual Investor Forum29 Dec 2025 - Hybrid medical device and SOL treasury strategy, with major warrant-driven capital raise.STSS
Registration Filing23 Dec 2025 - Dual medical device and SOL treasury strategy with $1B shelf, high risk and regulatory exposure.STSS
Registration Filing23 Dec 2025 - Expanding syringe production and global reach, with new supply deals and Nasdaq compliance actions.STSS
Registration Filing16 Dec 2025 - Safety syringe innovator secures major supply deal and maintains Nasdaq listing amid legal risks.STSS
Registration Filing16 Dec 2025 - Patented syringe maker secures $50M+ supply deal; 259,092 shares registered for resale.STSS
Registration Filing16 Dec 2025 - Dual focus on medical devices and a SOL-centric treasury strategy drives high risk and flexibility.STSS
Registration Filing16 Dec 2025 - IPO registers resale of shares and warrants, highlighting a strategic pivot to SOL-focused treasury.STSS
Registration Filing16 Dec 2025 - Raised $411M, held over 2M SOL, and posted a $105M net loss amid major restructuring.STSS
Q3 202512 Dec 2025